This proposal is for continuation of funding required to staff and operate the Statistical Office of the Gynecologic Oncology Group (GOG), a cooperative research group. It is the function of this office to collect, abstract, code, update, process, analyze and present the data submitted by member institutions. Additionally, the GOG Statistical Office plays a major role in the design, formatting and randomization of all new protocols, implements interim and final study chairman's reviews, and is the focal point for the preparation of all GOG abstracts and manuscripts for publication. A primary objective of the GOG Statistical Office during the upcoming grant period is the smooth integration of randomization, forms tracking, delinquency monitoring, and modality quality control into the GOG Statistical Office mechanism. These tasks were previously accomplished by GOG Operations Office but have been reassigned to the Statistical Office following the last site visit and corresponding critique. Our principal objective is to manage patient data in an efficient and accurate manner, resulting in timely analyses, logical and appropriate interpretation of results and relevant publications. the achievement of these goals will have direct bearing upon the future management of patients with gynecologic malignancies. The methodology involved consists of: (a) Involvement of GOG Statistical Office in all phases of study design, conduct, management and interpretation as mandated by GOG Protocol Procedures Manual; (b) Incorporation of randomization and quality control procedures into the GOG Statistical Office operation; (c) Expansion of Roswell Park Management Information Systems (RPMIS), using main-frame version of SIR to implement forms tracking and quality control; (d) Continued expanded use of computer evaluation sheets (EVL's) which facilitates interaction among study chairman, data abstractor, and statistician; thus, each protocol is thoroughly reviewed twice-yearly in order to resolve questions and incorporate comments or suggestions into the patient data. (e) Coordination, monitoring and preparation of all GOG publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037517-09
Application #
3558171
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1984-07-01
Project End
1994-03-31
Budget Start
1993-04-01
Budget End
1994-03-31
Support Year
9
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancerĀ treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Valicenti, Richard K; Pugh, Stephanie L; Trabulsi, Edouard J et al. (2018) First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys 100:695-701
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Monk, Bradley J; Kauderer, James T; Moxley, Katherine M et al. (2018) A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151:422-427
Hensley, Martee L; Enserro, Danielle; Hatcher, Helen et al. (2018) Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol :JCO1800454
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :
Boardman, Cecelia H; Brady, William E; Dizon, Don S et al. (2018) A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic On Gynecol Oncol 151:202-207
Felix, Ashley S; Cohn, David E; Brasky, Theodore M et al. (2018) Receipt of adjuvant endometrial cancer treatment according to race: anĀ NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol 219:459.e1-459.e11

Showing the most recent 10 out of 484 publications